Montelukast treatment response according to eosinophil-derived neurotoxin level in children with allergic rhinitis.
| Autor: | Lee YJ; Department of Pediatrics, Yonsei University College of Medicine, Yongin Severance Hospital, Yongin, Korea., Ma HS; Asthma and Allergy Center, Department of Pediatrics, Inje University Sanggye Paik Hospital, Seoul, Korea., Callaway Z; Asthma and Allergy Center, Department of Pediatrics, Inje University Sanggye Paik Hospital, Seoul, Korea.; Science Division, Mahidol University International College, Nakhon Pathom, Thailand., Kim CK; Asthma and Allergy Center, Department of Pediatrics, Inje University Sanggye Paik Hospital, Seoul, Korea. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2024 Dec; Vol. 61 (12), pp. 1611-1618. Date of Electronic Publication: 2024 Jun 28. |
| DOI: | 10.1080/02770903.2024.2370002 |
| Abstrakt: | Background: Eosinophil-derived neurotoxin (EDN) is an important biomarker of eosinophilic inflammation. Methods: This study evaluated Montelukast treatment response according to EDN concentration in children with perennial allergic rhinitis (PAR). Fifty-two children with PAR were recruited and took a combination of Montelukast (5mg) and Levocetirizine (5mg) "Mont/Levo Group" or only Montelukast (5mg) "Mont Group" for 4 weeks. All caregivers were instructed to record rhinitis symptoms for 4 weeks. EDN was measured before and after treatment. Results: Daytime nasal symptom scores (DNSS) significantly decreased in both the Mont/Levo ( p = 0.0001; n = 20) and Mont Group ( p < 0.0001; n = 20), but there were no significant differences between the two groups. EDN concentration also significantly decreased after treatment in both groups ( p < 0.0001 and p < 0.001, respectively). For secondary analysis, children with a high initial EDN concentration (EDN ≥ 53 ng/mL) were placed in the "High EDN Group", while those with a lower initial EDN concentration (EDN < 53 ng/mL) were put in the "Low EDN Group". Both groups experienced significant reductions in DNSS after either treatment regimen ( p < 0.0001 and p = 0.0027, respectively) but the High EDN Group had greater reductions. EDN concentrations in the High EDN Group decreased significantly from either treatment ( p < 0.0001). Conclusion: We found that children with AR and a high serum EDN concentration may respond well to Montelukast treatment. A therapeutic strategy using EDN concentrations in patients with AR to evaluate therapeutic response may help improve quality of care. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|